

Special Issue

Personalized Medicine in Gynecological Oncology: Update and Challenge

Message from the Guest Editor

Gynecological oncology has entered an era of precision medicine, where advances in molecular biology, imaging, and targeted therapies are reshaping how we diagnose and treat women with cancer. The integration of genomics, artificial intelligence, and advanced imaging techniques allows for increasingly individualised care, improving both oncological outcomes and quality of life. This Special Issue of the *Journal of Personalized Medicine*, dedicated to Gynecological Oncology, aims to bring together contributions that reflect the current progress and future directions of the field. Topics of interest include innovations in surgical and non-surgical management, imaging-based prediction models, molecular profiling, biomarkers for treatment response, and the role of minimally invasive and fertility-preserving approaches. By bridging translational research and clinical practice, this Special Issue seeks to emphasise the importance of personalised strategies that move beyond a “one-size-fits-all” paradigm, ensuring that every patient benefits from the most precise, effective, and compassionate care possible.

Guest Editor

Dr. Patrícia Pinto

Department of Gynecology, Instituto Português de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisbon, Portugal

Deadline for manuscript submissions

31 August 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/258642

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).